Yuji Sakai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuji Sakai has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
Harutoshi Sugiyama
Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan
39 shared publications- Toshio Tsuyuguchi
Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan
29 shared publications - Osamu Yokosuka
Chiba University, Chiba, Japan
22 shared publications Toshio Tsuyuguchi
Department of Gastroenterology, Chiba Prefectural Sawara Hospital, Sawara 287-0003, Japan
20 shared publicationsOsamu Yokosuka
Yuji Sakai, Toshio Tsuyuguchi, Osamu Yokosuka, Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
18 shared publicationsTakeshi Ishihara
18 shared publications
Latest Publications
- Open Access
- 5 June 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Pharmacology and Therapeutics
- Vol. 16 (2) , 105801
Efficacy of elobixibat for elderly patients with chronic constipation in a clinic
BACKGROUND Elobixibat reportedly improves bowel movements in patients with chronic constipation. However, its effect on bowel movements in elderly patients with chronic constipation in clinical settings has not been examined. AIM To examine bowel movement frequency and stool form before and after elobixibat administration in elderly patients with chronic constipation at our clinic. METHODS A total of 10 mg elobixibat was administered to 35 (< 65 years old) patients and 45 (≥ 65 years old) patients with chronic constipation. The frequency of bowel movements and stool forms, assessed using the Bristol Stool Form Scale (BSFS), were compared between the two groups 1 week before and after elobixibat administration. RESULTS In patients aged < 65 years with chronic constipation, the pre-elobixibat frequency of bowel movements and BSFS scores were 2.167 ± 0.732 and 2.286 ± 0.742, respectively. After elobixibat administration, the frequency of bowel movements and BSFS scores improved to 2.389 ± 0.502 and 3.995 ± 0.566, respectively, showing a significant improvement in bowel movement status. In patients aged ≥ 65 years with chronic constipation, the pre-elobixibat frequency of bowel movements and BSFS scores were 2.003 ± 0.733 and 2.217 ± 0.758, respectively. After elobixibat administration, the frequency of bowel movements and BSFS scores improved to 4.402 ± 1.346 and 3.800 ± 0.704, respectively, indicating an improvement in bowel movement status (P < 0.001). No significant differences were observed in the frequency and improvement status of bowel movements or BSFS scores between patients with chronic constipation aged ≥ 65 years and < 65 years. Adverse events due to the administration of elobixibat occurred in 16 cases (20%). No significant differences were found in the incidence of adverse events between patients with chronic constipation aged < 65 years (8 cases, 22.9%) and those aged ≥ 65 years (8 cases, 17.8%). CONCLUSION Elobixibat is effective in improving bowel movement status in patients with chronic constipation. No significant differences were found in the improvement of bowel movement status or the incidence of adverse events between patients with chronic constipation aged < 65 years and ≥ 65 years, suggesting that the drug may be safely used in elderly patients.
- 5 June 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Pharmacology and Therapeutics
- Vol. 16 (2) , 105801
Open AccessEfficacy of elobixibat for elderly patients with chronic constipation in a clinic
BACKGROUND Elobixibat reportedly improves bowel movements in patients with chronic constipation. However, its effect on bowel movements in elderly patients with chronic constipation in clinical settings has not been examined. AIM To examine bowel movement frequency and stool form before and after elobixibat administration in elderly patients with chronic constipation at our clinic. METHODS A total of 10 mg elobixibat was administered to 35 (< 65 years old) patients and 45 (≥ 65 years old) patients with chronic constipation. The frequency of bowel movements and stool forms, assessed using the Bristol Stool Form Scale (BSFS), were compared between the two groups 1 week before and after elobixibat administration. RESULTS In patients aged < 65 years with chronic constipation, the pre-elobixibat frequency of bowel movements and BSFS scores were 2.167 ± 0.732 and 2.286 ± 0.742, respectively. After elobixibat administration, the frequency of bowel movements and BSFS scores improved to 2.389 ± 0.502 and 3.995 ± 0.566, respectively, showing a significant improvement in bowel movement status. In patients aged ≥ 65 years with chronic constipation, the pre-elobixibat frequency of bowel movements and BSFS scores were 2.003 ± 0.733 and 2.217 ± 0.758, respectively. After elobixibat administration, the frequency of bowel movements and BSFS scores improved to 4.402 ± 1.346 and 3.800 ± 0.704, respectively, indicating an improvement in bowel movement status (P < 0.001). No significant differences were observed in the frequency and improvement status of bowel movements or BSFS scores between patients with chronic constipation aged ≥ 65 years and < 65 years. Adverse events due to the administration of elobixibat occurred in 16 cases (20%). No significant differences were found in the incidence of adverse events between patients with chronic constipation aged < 65 years (8 cases, 22.9%) and those aged ≥ 65 years (8 cases, 17.8%). CONCLUSION Elobixibat is effective in improving bowel movement status in patients with chronic constipation. No significant differences were found in the improvement of bowel movement status or the incidence of adverse events between patients with chronic constipation aged < 65 years and ≥ 65 years, suggesting that the drug may be safely used in elderly patients.
- Open Access
- 18 August 2024
- Published by Springer Nature in Cureus
- Vol. 16 (8) , e67133
Usefulness of Endoscopic Retrograde Cholangiopancreatography (ERCP)-Related Procedures for Gallstone Pancreatitis
Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (EST) are said to be useful procedures for gallstone pancreatitis. However, there have been few reports on a large number of patients to whom they were used. The clinical usefulness of ERCP and EST is herein examined retrospectively. Methods: ERCP and EST were performed to evaluate their clinical usefulness and safety in 108 patients who had gallbladder stones from December 1985 to October 2017 and were diagnosed as having gallstone pancreatitis. Of 108 patients, 83 were mild, and 25 were severe. Following the procedures, clinical courses were observed for three years in 108 patients who underwent the treatments. Results: Cholangiogram was successfully conducted in 108 patients. Bile duct stones were noted in 90 patients, and the stones were removed after EST. Of 18 patients who did not show bile duct stone in cholangiogram, 13 patients underwent EST, while five patients taking anticoagulants completed procedures only with cholangiogram. Accidental symptom was hemorrhage in three patients (2.7%; 3/108), but it was mild and conservatively resolving. During the three-year observation period, acute cholangitis was noted in three patients (2.7%; 3/108), but no relapsing pancreatitis was noted. Conclusions: It was suggested that ERCP and EST could be useful therapies for gallstone pancreatitis.
- 18 August 2024
- Published by Springer Nature in Cureus
- Vol. 16 (8) , e67133
Open AccessUsefulness of Endoscopic Retrograde Cholangiopancreatography (ERCP)-Related Procedures for Gallstone Pancreatitis
Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (EST) are said to be useful procedures for gallstone pancreatitis. However, there have been few reports on a large number of patients to whom they were used. The clinical usefulness of ERCP and EST is herein examined retrospectively. Methods: ERCP and EST were performed to evaluate their clinical usefulness and safety in 108 patients who had gallbladder stones from December 1985 to October 2017 and were diagnosed as having gallstone pancreatitis. Of 108 patients, 83 were mild, and 25 were severe. Following the procedures, clinical courses were observed for three years in 108 patients who underwent the treatments. Results: Cholangiogram was successfully conducted in 108 patients. Bile duct stones were noted in 90 patients, and the stones were removed after EST. Of 18 patients who did not show bile duct stone in cholangiogram, 13 patients underwent EST, while five patients taking anticoagulants completed procedures only with cholangiogram. Accidental symptom was hemorrhage in three patients (2.7%; 3/108), but it was mild and conservatively resolving. During the three-year observation period, acute cholangitis was noted in three patients (2.7%; 3/108), but no relapsing pancreatitis was noted. Conclusions: It was suggested that ERCP and EST could be useful therapies for gallstone pancreatitis.
- Open Access
- 18 August 2024
- Published by Springer Nature in Cureus
- Vol. 16 (8) , e67132
Usefulness of Elobixibat in Patients With Chronic Constipation After Cholecystectomy
Background: There have been reports that elobixibat improves bowel movements in patients with chronic constipation. However, no studies have been conducted to date to examine bowel movements after the administration of elobixibat in patients with chronic constipation in terms of the presence or absence of the gallbladder. In this study, we examined the frequency of bowel movements and stool forms in patients with gallbladders and post-cholecystectomy patients before and after the administration of elobixibat for chronic constipation. Methods: Elobixibat 10 mg was administered to treat chronic constipation in 40 patients with gallbladders and 18 patients who underwent cholecystectomy. The frequencies of bowel movements one week before and after elobixibat administration were compared between the two groups, using the Bristol Stool Form Scale (BSFS). Results: No significant difference in patient background with or without cholecystectomy was noted between the groups. In patients with gallbladders, the pre-dosing mean frequency of bowel movements was 2.389 +/- 0.502 with BSFS of 2.179 +/- 0.721 and the post-dosing mean frequency of bowel movements was 4.308 +/- 1.151 with BSFS of 3.718 +/- 1.521, indicating significant improvement in bowel movements (p < 0.001). In post-cholecystectomy patients, the pre-dosing mean frequency of bowel movements was 2.389 +/- 0.502 with BSFS of 2.222 +/- 0.647 and the post-dosing mean frequency of bowel movements was 4.222 +/- 1.734 with BSFS of 3.333 +/- 1.237, indicating significant improvement in bowel movements (p < 0.001). No significant difference in bowel movements was noted between patients with or without the gallbladder. Conclusions: Elobixibat is useful in improving the bowel movements of patients with chronic constipation. No significant difference was noted in the improvement of bowel movements due to cholecystectomy. It was suggested that even post-cholecystectomy patients could obtain therapeutic effects similar to patients with gallbladders.
- 18 August 2024
- Published by Springer Nature in Cureus
- Vol. 16 (8) , e67132
Open AccessUsefulness of Elobixibat in Patients With Chronic Constipation After Cholecystectomy
Background: There have been reports that elobixibat improves bowel movements in patients with chronic constipation. However, no studies have been conducted to date to examine bowel movements after the administration of elobixibat in patients with chronic constipation in terms of the presence or absence of the gallbladder. In this study, we examined the frequency of bowel movements and stool forms in patients with gallbladders and post-cholecystectomy patients before and after the administration of elobixibat for chronic constipation. Methods: Elobixibat 10 mg was administered to treat chronic constipation in 40 patients with gallbladders and 18 patients who underwent cholecystectomy. The frequencies of bowel movements one week before and after elobixibat administration were compared between the two groups, using the Bristol Stool Form Scale (BSFS). Results: No significant difference in patient background with or without cholecystectomy was noted between the groups. In patients with gallbladders, the pre-dosing mean frequency of bowel movements was 2.389 +/- 0.502 with BSFS of 2.179 +/- 0.721 and the post-dosing mean frequency of bowel movements was 4.308 +/- 1.151 with BSFS of 3.718 +/- 1.521, indicating significant improvement in bowel movements (p < 0.001). In post-cholecystectomy patients, the pre-dosing mean frequency of bowel movements was 2.389 +/- 0.502 with BSFS of 2.222 +/- 0.647 and the post-dosing mean frequency of bowel movements was 4.222 +/- 1.734 with BSFS of 3.333 +/- 1.237, indicating significant improvement in bowel movements (p < 0.001). No significant difference in bowel movements was noted between patients with or without the gallbladder. Conclusions: Elobixibat is useful in improving the bowel movements of patients with chronic constipation. No significant difference was noted in the improvement of bowel movements due to cholecystectomy. It was suggested that even post-cholecystectomy patients could obtain therapeutic effects similar to patients with gallbladders.
- Open Access
- 6 January 2024
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 12 (1) , 42-50
Natural history of asymptomatic gallbladder stones in clinic without beds: A long-term prognosis over 10 years
Several studies have explored the long-term prognosis of patients with asymp tomatic gallbladder stones. These reports were primarily conducted in facilities equipped with beds for addressing symptomatic cases. To report the long-term prognosis of patients with asymptomatic gallbladder stones in clinics without bed facilities. We investigated the prognoses of 237 patients diagnosed with asymptomatic gallbladder stones in clinics without beds between March 2010 and October 2022. When symptoms developed, patients were transferred to hospitals where appropriate treatment was possible. We investigated the asymptomatic and survival periods during the follow-up. Among the 237 patients, 214 (90.3%) remained asymptomatic, with a mean asymptomatic period of 3898.9279 ± 46.871 d (50-4111 d, 10.7 years on average). Biliary complications developed in 23 patients (9.7%), with a mean survival period of 4010.0285 ± 31.2788 d (53-4112 d, 10.9 years on average). No patient died of biliary complications. The long-term prognosis of asymptomatic gallbladder stones in clinics without beds was favorable. When the condition became symptomatic, the patients were transferred to hospitals with beds that could address it; thus, no deaths related to biliary complications were reported. This finding suggests that follow-up care in clinics without beds is possible.
- 6 January 2024
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 12 (1) , 42-50
Open AccessNatural history of asymptomatic gallbladder stones in clinic without beds: A long-term prognosis over 10 years
Several studies have explored the long-term prognosis of patients with asymp tomatic gallbladder stones. These reports were primarily conducted in facilities equipped with beds for addressing symptomatic cases. To report the long-term prognosis of patients with asymptomatic gallbladder stones in clinics without bed facilities. We investigated the prognoses of 237 patients diagnosed with asymptomatic gallbladder stones in clinics without beds between March 2010 and October 2022. When symptoms developed, patients were transferred to hospitals where appropriate treatment was possible. We investigated the asymptomatic and survival periods during the follow-up. Among the 237 patients, 214 (90.3%) remained asymptomatic, with a mean asymptomatic period of 3898.9279 ± 46.871 d (50-4111 d, 10.7 years on average). Biliary complications developed in 23 patients (9.7%), with a mean survival period of 4010.0285 ± 31.2788 d (53-4112 d, 10.9 years on average). No patient died of biliary complications. The long-term prognosis of asymptomatic gallbladder stones in clinics without beds was favorable. When the condition became symptomatic, the patients were transferred to hospitals with beds that could address it; thus, no deaths related to biliary complications were reported. This finding suggests that follow-up care in clinics without beds is possible.
- Open Access
- 10 August 2021
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 56 (10) , 1229-1235
Uncovered versus covered metallic stents for the management of unresectable malignant distal biliary obstruction: a randomized multicenter trial
The treatment result of the uncovered metallic stent (uncovered MS) and covered metallic stent (covered MS) for unresectable malignant distal biliary obstruction is controversial. This time, we con...
- 10 August 2021
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 56 (10) , 1229-1235
Open AccessUncovered versus covered metallic stents for the management of unresectable malignant distal biliary obstruction: a randomized multicenter trial
The treatment result of the uncovered metallic stent (uncovered MS) and covered metallic stent (covered MS) for unresectable malignant distal biliary obstruction is controversial. This time, we con...
- Open Access
- 21 April 2021
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 27 (15) , 1569-1577
Current status of diagnosis and therapy for intraductal papillary neoplasm of the bile duct
Current status of diagnosis and therapy for intraductal papillary neoplasm of the bile duct
- 21 April 2021
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 27 (15) , 1569-1577
Open AccessCurrent status of diagnosis and therapy for intraductal papillary neoplasm of the bile duct
Current status of diagnosis and therapy for intraductal papillary neoplasm of the bile duct
- Open Access
- 11 March 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (3) , 498
Percutaneous Two-Dimensional Shear Wave Elastography for Diagnosis of Pancreatic Tumor
Background: To investigate the efficacy of two-dimensional shear wave elastography (2D-SWE) for the diagnosis of pancreatic mass lesions. Methods: This ethics committee–approved cross-sectional study included 52 patients with histologically-proven pancreatic tumors (pancreatic ductal adenocarcinoma (PDAC), 36; tumor-forming pancreatitis (TFP), 15; neuroendocrine tumor, 1) and 33 control subjects. The 2D-SWE was performed for the tumor/non-tumor tissues, and SWE-mapping patterns and propagation quality were assessed. Results: Three mapping patterns were detected based on the size and distribution of the coloring areas. Pattern A (whole coloring) was detected in all non-tumor tissues and TFP, whereas pattern C (multiple small coloring spots) was detected in PDAC only. Pattern B (partial coloring with smaller spots) was detected in other lesions. The specificity and positive predictive value of pattern A for non-PDAC and those of pattern C for PDAC were 100%. The SWE value was higher in tumor lesions than in the non-tumor tissues (38.1 vs. 9.8 kPa; p < 0.001) in patients with PDAC. The SWE value in the non-tumor lesion was higher in patients with PDAC than in control (9.8 vs. 7.5 kPa; p < 0.001). Conclusions: 2D-SWE may play a role as a novel diagnostic tool for PDAC to detect a specific mapping pattern with quantitative assessment.
- 11 March 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (3) , 498
Open AccessPercutaneous Two-Dimensional Shear Wave Elastography for Diagnosis of Pancreatic Tumor
Background: To investigate the efficacy of two-dimensional shear wave elastography (2D-SWE) for the diagnosis of pancreatic mass lesions. Methods: This ethics committee–approved cross-sectional study included 52 patients with histologically-proven pancreatic tumors (pancreatic ductal adenocarcinoma (PDAC), 36; tumor-forming pancreatitis (TFP), 15; neuroendocrine tumor, 1) and 33 control subjects. The 2D-SWE was performed for the tumor/non-tumor tissues, and SWE-mapping patterns and propagation quality were assessed. Results: Three mapping patterns were detected based on the size and distribution of the coloring areas. Pattern A (whole coloring) was detected in all non-tumor tissues and TFP, whereas pattern C (multiple small coloring spots) was detected in PDAC only. Pattern B (partial coloring with smaller spots) was detected in other lesions. The specificity and positive predictive value of pattern A for non-PDAC and those of pattern C for PDAC were 100%. The SWE value was higher in tumor lesions than in the non-tumor tissues (38.1 vs. 9.8 kPa; p < 0.001) in patients with PDAC. The SWE value in the non-tumor lesion was higher in patients with PDAC than in control (9.8 vs. 7.5 kPa; p < 0.001). Conclusions: 2D-SWE may play a role as a novel diagnostic tool for PDAC to detect a specific mapping pattern with quantitative assessment.
- 15 June 2018
- Published by Japan Gastrointestinal Endoscopy Society in Progress of Digestive Endoscopy
- Vol. 92 (1) , 69-73
Characteristics and clinical outcomes of endoscopic transpapillary gallbladder drainage
【目的】急性胆囊疾患に対する内視鏡的経乳頭的胆囊ドレナージ術の治療成績を分析し,その特徴を明らかにすること.【対象と方法】2012年1月から2017年10月までの期間において,治療目的で内視鏡的経乳頭的胆囊ドレナージ術を試みた25例を後方視的に調査した.【結果】治療対象とした急性胆囊疾患の内訳は,急性胆囊炎が22例(88%),胆囊出血2例(8%),胆囊穿孔1例(4%)であった.技術的成功率は76%(19/25例)で,内視鏡的経乳頭的胆囊ステント留置術を13例,内視鏡的経鼻胆囊ドレナージ術を6例に行っていた.技術的成功例の中での臨床的成功率は,84%(16/19例)であった.臨床的不成功となったのは,胆囊出血に対して内視鏡的経鼻胆囊ドレナージ術を行った2例と,軽症急性胆囊炎に対する内視鏡的経乳頭的胆囊ステント留置術後に遅発性胆囊穿孔が起きた1例であり,これら3例は外科手術となった.偶発症は2例(8%)で起こり,胆囊管穿孔1例と遅発性胆囊穿孔1例であった.【考察】検討対象となった全25例において,内視鏡的経乳頭的胆囊ドレナージ術は16例(64%)の症例に有効であった.経乳頭的胆囊ドレナージ術は,経皮経肝胆囊ドレナージ術が適さない胆囊炎で,胆囊出血がない場合に治療選択肢の1つとなると考えられた.
- 15 June 2018
- Published by Japan Gastrointestinal Endoscopy Society in Progress of Digestive Endoscopy
- Vol. 92 (1) , 69-73
Characteristics and clinical outcomes of endoscopic transpapillary gallbladder drainage
【目的】急性胆囊疾患に対する内視鏡的経乳頭的胆囊ドレナージ術の治療成績を分析し,その特徴を明らかにすること.【対象と方法】2012年1月から2017年10月までの期間において,治療目的で内視鏡的経乳頭的胆囊ドレナージ術を試みた25例を後方視的に調査した.【結果】治療対象とした急性胆囊疾患の内訳は,急性胆囊炎が22例(88%),胆囊出血2例(8%),胆囊穿孔1例(4%)であった.技術的成功率は76%(19/25例)で,内視鏡的経乳頭的胆囊ステント留置術を13例,内視鏡的経鼻胆囊ドレナージ術を6例に行っていた.技術的成功例の中での臨床的成功率は,84%(16/19例)であった.臨床的不成功となったのは,胆囊出血に対して内視鏡的経鼻胆囊ドレナージ術を行った2例と,軽症急性胆囊炎に対する内視鏡的経乳頭的胆囊ステント留置術後に遅発性胆囊穿孔が起きた1例であり,これら3例は外科手術となった.偶発症は2例(8%)で起こり,胆囊管穿孔1例と遅発性胆囊穿孔1例であった.【考察】検討対象となった全25例において,内視鏡的経乳頭的胆囊ドレナージ術は16例(64%)の症例に有効であった.経乳頭的胆囊ドレナージ術は,経皮経肝胆囊ドレナージ術が適さない胆囊炎で,胆囊出血がない場合に治療選択肢の1つとなると考えられた.
- Open Access
- 7 January 2018
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 24 (1) , 69-75
Safety and efficacy of metallic stent for unresectable distal malignant biliary obstruction in elderly patients
AIM To study the safety of insertion of metallic stents in elderly patients with unresectable distal malignant biliary obstruction. METHODS Of 272 patients with unresectable distal malignant biliary obstruction, 184 patients under the age of 80 were classified into Group A, and 88 subjects aged 80 years or more were classified into Group B. The safety of metallic stent insertion, metal stent patency period, and the obstruction rate were examined in each group. RESULTS In Group B, patients had a significantly worse performance status, high blood pressure, heart disease, cerebrovascular disease, and dementia; besides the rate of patients orally administered antiplatelet drugs or anticoagulants tended to be higher (P < 0.05). Metallic stents were successfully inserted in all patients. The median patency period was 265.000 +/- 26.779 (1-965) d; 252.000 +/- 35.998 (1-618) d in Group A and 269.000 +/- 47.885 (1-965) d in Group B, with no significant difference between the two groups. Metallic stent obstruction occurred in 82 of the 272 (30.15%) patients; in 53/184 (28.80%) patients in Group A and in 29/88 (32.95%) of those in Group B, showing no significant difference between the two groups. Procedural accidents due to metal stent insertion occurred in 24/272 (8.8%) patients; in 17/184 (9.2%) of patients in Group A and in 7/88 (8.0%) of those in Group B, with no significant difference between the two groups, either. CONCLUSION These results suggested that metallic stents can be safely inserted to treat unresectable distal malignant biliary obstruction even in elderly patients aged 80 years or more.
- 7 January 2018
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 24 (1) , 69-75
Open AccessSafety and efficacy of metallic stent for unresectable distal malignant biliary obstruction in elderly patients
AIM To study the safety of insertion of metallic stents in elderly patients with unresectable distal malignant biliary obstruction. METHODS Of 272 patients with unresectable distal malignant biliary obstruction, 184 patients under the age of 80 were classified into Group A, and 88 subjects aged 80 years or more were classified into Group B. The safety of metallic stent insertion, metal stent patency period, and the obstruction rate were examined in each group. RESULTS In Group B, patients had a significantly worse performance status, high blood pressure, heart disease, cerebrovascular disease, and dementia; besides the rate of patients orally administered antiplatelet drugs or anticoagulants tended to be higher (P < 0.05). Metallic stents were successfully inserted in all patients. The median patency period was 265.000 +/- 26.779 (1-965) d; 252.000 +/- 35.998 (1-618) d in Group A and 269.000 +/- 47.885 (1-965) d in Group B, with no significant difference between the two groups. Metallic stent obstruction occurred in 82 of the 272 (30.15%) patients; in 53/184 (28.80%) patients in Group A and in 29/88 (32.95%) of those in Group B, showing no significant difference between the two groups. Procedural accidents due to metal stent insertion occurred in 24/272 (8.8%) patients; in 17/184 (9.2%) of patients in Group A and in 7/88 (8.0%) of those in Group B, with no significant difference between the two groups, either. CONCLUSION These results suggested that metallic stents can be safely inserted to treat unresectable distal malignant biliary obstruction even in elderly patients aged 80 years or more.
- 24 October 2017
- Published by Springer Nature
- p. 351-365
Peroral Cholangioscopy for the Diagnosis of Biliary Tract Diseases
- 24 October 2017
- Published by Springer Nature
- p. 351-365
Peroral Cholangioscopy for the Diagnosis of Biliary Tract Diseases